Global Epilepsy Drugs Market (2020 to 2027) - Featuring UCB, Eisai, H. Lundbeck and GW Pharmaceuticals
September 15, 2021 04:28 ET
|
Research and Markets
Dublin, Sept. 15, 2021 (GLOBE NEWSWIRE) -- The "Epilepsy Drugs Market, Global Forecast, Impact of COVID-19, Industry Trends, by Drugs Category, Growth, Opportunity Company Analysis" report has been...
Adamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy
May 22, 2017 08:30 ET
|
Adamas Pharmaceuticals, Inc.
-- Phase 1 results show ADS-4101 is better tolerated in healthy volunteers than equivalent doses of VIMPAT® (lacosamide) immediate-release tablets -- -- Multi-dose Phase 1b steady state study...
Adamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with Epilepsy
January 03, 2017 16:52 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the completion of a Phase 1 clinical trial of ADS-4101, an investigational drug in...